Table 3.
Clinical studies on immunotherapy agents currently conducted in melanoma
| Study | Combination | Description |
|---|---|---|
| NCT02967692 | PD1 inhibitor, BRAFi, MEKi | Phase III study evaluating efficacy and safety of melanoma treatment composed of novel anti-PD1 antibody and targeted therapy |
| NCT02908672 | PD-L1 inhibitor, BRAFi, MEKi | Phase III study of efficacy of atezolizumab, vemurafenib and dabrafenib combination in unresectable or metastatic melanoma |
| NCT02752074 | PD1, IDO1 | Phase III study of pembrolizumab and epacadostat/placebo in advanced melanoma |
| NCT02705482 | PD-L1 inhibitor/CTLA-4 inhibitor, OX40 agonist | Phase I trial evaluating safety and pharmacokinetics of novel OX40 agonist, MEDI0562, in combination with durvalumab or tremelimumab (anti-PD-L1 and anti-CTLA-4 respectively) in adult subjects with select advanced solid tumors |
| NCT02983045 | PD1 inhibitor, CD122 | Phase I/II study of nivolumab and novel CD122-based stimulating cytokine in NSCLC, RCC and melanoma |
| NCT01239134 | GITR inhibitor | Phase 1b study determining the safety, tolerability, pharmacokinetic of activating GITR antibody, TRX518 in advanced melanoma or other solid tumors |
| NCT02676869 | PD1 inhibitor, LAG3 inhibitor | Phase I study of IMP321, novel LAG3 inhibitor combined with pembrolizumab in unresectable or metastatic melanoma |
| NCT02460224 | PD1 inhibitor, LAG3 inhibitor | Phase I/II trial of safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 (anti-PD1) in melanoma, NSCLC and RCC |
| NCT02475213 | PD1 inhibitor, B7-H3 inhibitor | Phase I study of safety of enoblituzumab in combination with pembrolizumab in selected solid tumors expressing B7-H3 |
| NCT01714739 | PD1 inhibitor, KIR inhibitor, CTLA-4 inhibitor | Phase I/II study assessing the safety and tolerability of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab in advanced solid tumors |
| NCT02817633 | PD1 inhibitor, TIM-3 inhibitor | Phase I, first-in-human, study evaluating safety and tolerability of the anti-TIM-3 antibody TSR-022 with or without an anti-PD-1 antibody in advanced solid tumors |
| NCT02608268 | PD1 inhibitor, TIM-3 inhibitor | Phase I/II, first-in-human, study evaluating safety and tolerability of the anti-TIM-3 antibody MBG453 with or without an anti-PD-1 antibody in advanced solid tumors |
| NCT02598960 | GITR agonist, PD1 inhibitor | Phase I/II study evaluating safety and efficacy of BMS-986156 (GITR agonist) Administered Alone and in Combination With Nivolumab in advanced solid tumors |